Colucci to head Publicis Healthcare; Goldstone to DDB

Share this article:
Publicis promoted Nick Colucci to president and CEO of Publicis Healthcare Communications Group (PHCG). Colucci, who was previously COO of the group, replaces Ed Rady, who is retiring. He reports to John Farrell, president and CEO of Publicis’ Specialized Agencies & Marketing Services division. Colucci joined Medicus in 1997 and became president of the company in 2000. Rady, who has been named chairman, will remain on in that role through the year. PHCG includes Saatchi & Saatchi Healthcare Communications, Medicus, Lifebrands and BrandPharm and Williams-Labadie along with Publicis Selling Solutions. Separately, PHCG EVP Mark Goldstone joined Omnicom’s DDB Healthcare as president. Goldstone reports to DDB president and CEO Chuck Brymer.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...